Aurora Investment Counsel Takes Position in MiMedx Group Inc (MDXG)

Aurora Investment Counsel bought a new stake in shares of MiMedx Group Inc (NASDAQ:MDXG) in the fourth quarter, according to its most recent disclosure with the Securities and Exchange Commission. The fund bought 12,400 shares of the medical equipment provider’s stock, valued at approximately $156,000.

A number of other hedge funds and other institutional investors have also recently modified their holdings of the business. Pinebridge Investments L.P. raised its position in MiMedx Group by 2.9% during the 2nd quarter. Pinebridge Investments L.P. now owns 13,438 shares of the medical equipment provider’s stock valued at $201,000 after purchasing an additional 377 shares in the last quarter. Ameritas Investment Partners Inc. raised its position in MiMedx Group by 7.5% during the 2nd quarter. Ameritas Investment Partners Inc. now owns 8,619 shares of the medical equipment provider’s stock valued at $129,000 after purchasing an additional 600 shares in the last quarter. Amalgamated Bank raised its position in MiMedx Group by 5.9% during the 2nd quarter. Amalgamated Bank now owns 14,292 shares of the medical equipment provider’s stock valued at $214,000 after purchasing an additional 792 shares in the last quarter. PNC Financial Services Group Inc. raised its position in MiMedx Group by 0.8% during the 2nd quarter. PNC Financial Services Group Inc. now owns 104,747 shares of the medical equipment provider’s stock valued at $1,569,000 after purchasing an additional 816 shares in the last quarter. Finally, Dimensional Fund Advisors LP raised its position in MiMedx Group by 2.4% during the 2nd quarter. Dimensional Fund Advisors LP now owns 42,357 shares of the medical equipment provider’s stock valued at $634,000 after purchasing an additional 982 shares in the last quarter. 69.21% of the stock is owned by institutional investors and hedge funds.

A number of brokerages have weighed in on MDXG. BidaskClub lowered MiMedx Group from a “hold” rating to a “sell” rating in a research report on Friday. Lake Street Capital set a $18.00 target price on MiMedx Group and gave the company a “buy” rating in a research report on Thursday, December 14th. Zacks Investment Research lowered MiMedx Group from a “hold” rating to a “sell” rating in a research report on Friday, December 8th. Piper Jaffray Companies reissued a “buy” rating and issued a $18.00 price target on shares of MiMedx Group in a research report on Friday, December 1st. Finally, Needham & Company LLC reissued a “buy” rating and issued a $21.00 price target on shares of MiMedx Group in a research report on Friday, December 1st. Three analysts have rated the stock with a sell rating and three have assigned a buy rating to the stock. The stock currently has a consensus rating of “Hold” and a consensus price target of $17.00.

MiMedx Group Inc (MDXG) opened at $13.29 on Friday. The company has a market capitalization of $1,480.00, a price-to-earnings ratio of 44.30, a PEG ratio of 1.68 and a beta of 0.88. MiMedx Group Inc has a 1 year low of $7.64 and a 1 year high of $17.47.

MiMedx Group (NASDAQ:MDXG) last released its quarterly earnings results on Thursday, October 26th. The medical equipment provider reported $0.08 EPS for the quarter, hitting the Thomson Reuters’ consensus estimate of $0.08. The firm had revenue of $84.60 million during the quarter, compared to analyst estimates of $84.60 million. MiMedx Group had a return on equity of 17.49% and a net margin of 11.64%. The business’s revenue for the quarter was up 31.4% compared to the same quarter last year. During the same period in the previous year, the company posted $0.06 EPS. equities analysts anticipate that MiMedx Group Inc will post 0.23 EPS for the current year.

MiMedx Group declared that its board has approved a stock buyback program on Monday, October 9th that authorizes the company to repurchase $10.00 million in shares. This repurchase authorization authorizes the medical equipment provider to repurchase shares of its stock through open market purchases. Shares repurchase programs are often an indication that the company’s management believes its stock is undervalued.

COPYRIGHT VIOLATION WARNING: This story was originally published by Community Financial News and is the property of of Community Financial News. If you are reading this story on another publication, it was stolen and republished in violation of U.S. and international copyright & trademark laws. The correct version of this story can be read at https://www.com-unik.info/2018/01/06/aurora-investment-counsel-takes-position-in-mimedx-group-inc-mdxg.html.

MiMedx Group Profile

MiMedx Group, Inc is an integrated developer, processor and marketer of regenerative biomaterial products and bioimplants human placental tissue, skin and bone. The Company’s Regenerative Biomaterials segment includes the design, manufacture, and marketing of products and tissue processing services for the Wound Care, Surgical, Sports Medicine, Ophthalmic and Dental market categories.

Institutional Ownership by Quarter for MiMedx Group (NASDAQ:MDXG)

What are top analysts saying about MiMedx Group? - Enter your email address in the form below to receive our free daily email newsletter that contains the latest headlines and analysts' recommendations for for MiMedx Group and related companies.

Comments

Leave a Reply


share news on Facebook
tweet this investment news
share on linkedin
share on StockTwits
share on Google Plus
share on reddit